Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | TARS1 | P26639 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449289 | 1.00 | MME (0.50) | MMETGFBR1CTSCACEPDCD1LG2 | |
| SCHEMBL29746975 | 0.96 | MME (0.47) | MMETGFBR1CTSCACEPDCD1LG2 | |
| SCHEMBL29849851 | 0.93 | MME (0.45) | MMETGFBR1CTSCACEPDCD1LG2 | |
| SCHEMBL31696976 | 0.92 | MME (0.44) | MMETGFBR1CTSCACEPDCD1LG2 | |
| SCHEMBL30406096 | 0.91 | MME (0.54) | MMETGFBR1CTSC | |
| SCHEMBL30011153 | 0.89 | MME (0.42) | MMETGFBR1CTSCPDCD1LG2CD274 | |
| SCHEMBL30340139 | 0.89 | PDCD1LG2 (0.51) | MMETGFBR1CTSCPDCD1LG2CD274 | |
| SCHEMBL30906339 | 0.88 | MME (0.41) | MMETGFBR1CTSCPDCD1LG2CD274 | |
| Trifluoroacetic Acid SCHEMBL4092935 | 0.88 | MME (0.41) | MMETGFBR1CTSCACEPDCD1LG2 | |
| SCHEMBL29564528 | 0.87 | ACE (0.54) | MMETGFBR1CTSCACEPDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250145828-A1 | TRANSPARENT PROTEIN MATERIALS | TANDEM REPEAT TECHNOLOGIES, INC. | 2025-05-08 | — | — | US | claimed |
| CN-114190531-B | Preparation of mackerel flavor peptide and preparation method and application thereof | 浙江万里学院 | 2023-12-12 | — | — | CN | claimed |
| CN-116769860-A | Enzymatic hydrolysis of crayfish shells, oligopeptide family extracted from crayfish shells and application of crayfish shells | 奇明达(北京)植物药物技术开发有限公司 | 2023-09-19 | — | — | CN | claimed |
| WO-2023158960-A2 | TRANSPARENT PROTEIN MATERIALS | TANDEM REPEAT TECHNOLOGIES, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| EP-4107183-A1 | ANTI-CD19/ANTI-CD3 BISPECIFIC ANTIBODY, T CELLS SECRETING THE SAME, METHOD OF PREPARATION AND USE THEREOF | Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre (ES) | 2022-12-28 | — | — | EP | claimed |
| US-11518794-B2 | Synthesis method for liraglutide with low racemate impurity | Shenzhen JYMed Technology Co., Ltd. (CN) | 2022-12-06 | — | — | US | claimed |
| US-12559564-B2 | Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ASTRAZENECA AB (SE) | 2026-02-05 | — | — | US | disclosed |
| EP-4680631-A1 | COMBOTOPE ANTIBODY LIBRARIES | Danmarks Tekniske Universitet (DK) | 2026-01-21 | — | — | EP | disclosed |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| CN-112521471-B | Gene and molecular marker for controlling water content of corn kernels and application thereof | 华中农业大学 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022056200-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING ANTITUMORAL IMMUNE RESPONSES THROUGH TARGETING OF NTPDASE3 | Purinomia Biotech, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220062375-A1 | Compositions and Methods for Dengue Virus Chimeric Constructions in Vaccines | TAKEDA VACCINES, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| CN-114127121-A | Methods and compositions for promoting and enhancing T cell-mediated immune responses by ADCC targeting of CD39 expressing cells | 北京恩瑞尼生物科技股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11248034-B2 | Insulin analogs | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | MME 887/4885TGFBR1 2372/4885CTSC 1051/4885 |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | MME 1189/4885TGFBR1 2486/4885CTSC 26/4885 |
| US-12559564-B2 | Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis | ENTPD1, FCGR2A, FCGR1A | MME 560/4885TGFBR1 708/4885CTSC 852/4885 |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | MME 887/4885TGFBR1 2372/4885CTSC 1051/4885 |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | MME 455/4885TGFBR1 3013/4885CTSC 643/4885 |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ATP5ME, ATP5MF, ATP5MK | MME 298/4885TGFBR1 3678/4885CTSC 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.